Dendritic Cell-Based Cancer Vaccines
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About Celica Biomedical
Celica Biomedical is a privately held, pre-revenue Slovenian research institute founded in 2000, specializing in neuroscience (particularly astrocyte biology) and oncology immunotherapies. The company leverages a deep scientific foundation in regulated exocytosis and cell physiology to develop novel treatment strategies for CNS disorders and cancer vaccines. It operates a quality-managed laboratory, secures public research funding, and collaborates internationally, positioning itself to bridge the gap between academic discovery and clinical application.
View full company profileOther Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |